Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments...
Roche
Roche has lifted the lid on the data behind its second phase 3 giredestrant win,...
Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the...
Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies...
Roche may have been exploring ways to shuttle drugs to the brain for well over...
Roche has headed back to China to pen a licensing deal worth more than $1...
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business...
Roche is forging ahead with plans to seek approval for an eye disease drug candidate...
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by...
Roche, which currently has investigational Alzheimer’s disease drug trontinemab in phase 3 trials, has secured...